Approved accessible "empagliflozin and linagliptin tablets"

GLYXAMBI is a prescription medicine that contains 2 diabetes medicines, empagliflozin (JARDIANCE) and linagliptin (TRADJENTA).  GLYXAMBI can be used: o along with diet and exercise to lower blood sugar in adults with type 2 diabetes, o in adults with type 2 diabetes who have known cardiovascular disease when both empagliflozin (JARDIANCE) and linagliptin (TRADJENTA) is appropriate and empagliflozin (JARDIANCE) is needed to reduce the risk of cardiovascular death. • GLYXAMBI is not for people with type 1 diabetes. • GLYXAMBI is not for people with diabetic ketoacidosis (increased ketones in the blood or urine). • If you have had pancreatitis in the past, it is not known if you have a higher chance of getting pancreatitis while you take GLYXAMBI. It is not known if GLYXAMBI is safe and effective in children under 18 years of age.

Active ingredients: empagliflozin and linagliptin Inactive ingredients: mannitol, pregelatinized starch, corn starch, copovidone, crospovidone, talc and magnesium stearate. The film coating contains the following inactive ingredients:  hypromellose, mannitol, talc, titanium dioxide, polyethylene glycol. 10 mg/5 mg tablets also contain yellow ferric oxide. 25 mg/5 mg tablets also contain red ferric oxide.

How To access empagliflozin and linagliptin tablets?

GLYXAMBI (empagliflozin and linagliptin) tablets for oral use Initial U.S. Approval: 2015
To access empagliflozin and linagliptin tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)